Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource, 1 online resource.
Language
Englisch

Bibliographic citation
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study ; volume:46 ; number:9 ; day:28 ; month:6 ; year:2023 ; pages:835-845 ; date:9.2023
Drug safety ; 46, Heft 9 (28.6.2023), 835-845, 9.2023

Creator
Cornblath, David R.
van Doorn, Pieter A.
Hartung, Hans-Peter
Merkies, Ingemar S. J.
Katzberg, Hans D.
Hinterberger, Doris
Clodi, Elisabeth
Contributor
SpringerLink (Online service)

DOI
10.1007/s40264-023-01326-z
URN
urn:nbn:de:101:1-2023110607462136677510
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Cornblath, David R.
  • van Doorn, Pieter A.
  • Hartung, Hans-Peter
  • Merkies, Ingemar S. J.
  • Katzberg, Hans D.
  • Hinterberger, Doris
  • Clodi, Elisabeth
  • SpringerLink (Online service)

Other Objects (12)

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy

Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?

Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?

How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast

How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast

Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab

Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab

Reversible conduction failure in acute inflammatory demyelinating polyneuropathy

Reversible conduction failure in acute inflammatory demyelinating polyneuropathy

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy

Clinical and neurophysiological correlation in axonal and demyelinating polyneuropathy

Clinical and neurophysiological correlation in axonal and demyelinating polyneuropathy

IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV

IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV

Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy

Underdiagnosis and diagnostic delay in chronic inflammatory demyelinating polyneuropathy

Tubercular Meningitis with Acute Inflammatory Demyelinating Polyneuropathy—Trigger or Chance

Tubercular Meningitis with Acute Inflammatory Demyelinating Polyneuropathy—Trigger or Chance

Related objects